Literature DB >> 33414356

Patent Hemostasis Impact in Clinical Routine: Large Monocentric Echo-Doppler Study of Radial Artery Patency After Coronary Catheterization.

Alain Rougé1, Benjamin Faurie, Mohamed Abdellaoui, Jacques Monségu.   

Abstract

BACKGROUND: Radial access is currently the first line of access in interventional cardiology. Nevertheless, this technique carries a 1%-10% risk of radial artery occlusion (RAO) based on series.
METHODS: We conducted a large-scale echo-Doppler evaluation of radial patency including prospectively all patients who underwent coronary angiography and/or angioplasty with radial catheterization at our center in 2018.
RESULTS: A total of 1106 patients were enrolled in the cohort. Average patient age was 70 years, 24.5% were females and 75.5% were males, and 28.3% were diabetics. Five Fr and 6 Fr devices were used in 527 procedures and 565 procedures, respectively. Our study highlighted a very low RAO rate (0.99%). These results are mainly due to the high attention given to patent hemostasis, which was achieved in 1091 patients (98.6%). According to the literature, female gender is a multivariate predictive factor of RAO (P<.01). Furthermore, we confirm the protective nature of heparin (P=.04) with an average heparin dose of 69.73 IU/kg.
CONCLUSIONS: Our study focused on a large population with 1106 patients who underwent radial catheterization shows that a very low rate of RAO (0.99%) can be achieved. These results are correlated with a high attention to patent hemostasis and a close collaboration between the medical and paramedical staff.

Entities:  

Keywords:  RAO; patent hemostasis; radial access; radial artery occlusion

Year:  2021        PMID: 33414356

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  1 in total

1.  Incidence and predictors of radial artery occlusion following transradial coronary angiography: the proRadial trial.

Authors:  Julia Schlosser; Laura Herrmann; Tanja Böhme; Karlheinz Bürgelin; Nikolaus Löffelhardt; Thomas Nührenberg; Kambis Mashayekhi; Christian M Valina; Franz-Josef Neumann; Willibald Hochholzer
Journal:  Clin Res Cardiol       Date:  2022-09-08       Impact factor: 6.138

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.